This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ADMA Biologics Stock Skyrockets 262.1% YTD: How to Play the Stock?
by Ekta Bagri
ADMA stock rallies 262.1% in the year-to-date period on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?
by Ekta Bagri
ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday
by Zacks Equity Research
A Bloomberg article suggests that Brookfield Asset Management is in discussions with banks to raise nearly $11 billion to fund the takeover of Spain-based Grifols (GRFS).
ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?
by Ekta Bagri
The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Here's Why Grifols (GRFS) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Grifols (GRFS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Here's Why Grifols (GRFS) is Poised for a Turnaround After Losing -31.55% in 4 Weeks
by Zacks Equity Research
Grifols (GRFS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
3 Cheap Stocks to Buy for Growth & Value
by Shaun Pruitt
From their current levels, it would be no surprise if Direct Digital (DRCT), Vaalco Energy (EGY), and Grifols' (GRFS) stock moved much higher in 2024.
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Are You Looking for a Top Momentum Pick? Why Grifols (GRFS) is a Great Choice
by Zacks Equity Research
Does Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Best Breakout Stocks to Invest in for Attractive Returns
by Tirthankar Chakraborty
Grifols (GRFS), Denison Mine Corp (DNN), NGL Energy Partners (NGL), Macatawa Bank (MCBC) and Navient (NAVI) have been selected as the breakout stocks for today.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
GRFS or STVN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. STVN: Which Stock Is the Better Value Option?
Grifols (GRFS) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Should Value Investors Buy Grifols (GRFS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks for September 12th
by Zacks Equity Research
TAC, GRFS, KB, BRO and GRNT have been added to the Zacks Rank #1 (Strong Buy) List on September 12, 2023.
Should Value Investors Buy Grifols (GRFS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.